Pseudotumor cerebri during Cushing’s disease treatment with ketoconazole

Fabiola Costenaro 1, Ticiana C. Rodrigues 1, Nelson P. Ferreira 2, Tiago G. da Costa 3, Tiago Schuch 1, Vitor Boschi 1, Mauro A. Czepielewski 1,4

SUMMARY
Benign intracranial hypertension (Pseudotumor cerebri) has been described as related to the reduction in steroid levels in Cushing’s disease (CD), especially after surgical remission. Ketoconazole is a common and effective adjuvant therapy for hypercortisolism, but the major concern is liver enzyme dysfunction. We describe here the case of a 12-year old girl with CD who developed benign intracranial hypertension during treatment with ketoconazole. She presented headache, vomiting, a black spot on her right temporal visual field, and signs of elevated intracranial pressure. Pituitary image was normal on magnetic resonance image (MRI), and all symptoms improved after treatment with acetazolamide. We call attention to the diagnosis of this disorder in CD patients, especially children on ketoconazole treatment, because it could be confounded with adrenal insufficiency and lead to definitive severe visual impairment.

INTRODUCTION
Cushing’s disease (CD) patients may be a group at risk for benign intracranial hypertension as a consequence of the long suppression of normal pituitary corticotrophs, exposure to high circulating levels of serum cortisol, and abrupt and intense drop of cortisol levels with intervention. Patients effectively treated for hypercortisolism present reduction in the levels of these hormones, what may affect control of brain volume and lead to increased intracranial pressure (1). It is thought that altered cerebrospinal fluid (CSF) absorption gradient across the arachnoid villi may be the primary factor in resetting intracranial fluid compartments (2). There are some reports of benign intracranial hypertension, also called pseudotumor cerebri, associated with CD as a result of the reduction in corticosteroid levels after treatment with metyrapone, aminoglutethimide (1,3), and mitotane (4), or after a reduction in steroid levels in patients treated with pituitary surgery (3,5-7). Adrenal deficiency symptoms, such as headache and nausea, can be manifestations of intracranial hypertension in patients who have recently had the levels of exogenous or endogenous corticosteroids reduced.
Pseudotumor cerebri syndrome is characterized by headache, nausea/vomiting, papilledema and elevated CSF pressure (> 200 mm H₂O), with normal neurological examination (except for sixth nerve palsy and other problems secondary to intracranial hypertension), normal brain image, and normal CSF content (8,9). The major threat to patients with pseudotumor cerebri is loss of vision. Severe deficits occurred in 4%-12% of patients in a follow-up of four series (10). Usually, pseudotumor cerebri symptoms occur between 2 and 4 weeks after treatment of hypercortisolism or withdrawal of steroid replacement (5,6,11).

Recently, Kiehna and cols. reported seven cases of pseudotumor cerebri in 941 patients with CD who had pituitary surgery, a prevalence of about 0.7%. All these cases were diagnosed among pediatric patients (prevalence of 3%) during the first year after surgical treatment (3).

Here, we present a case of pseudotumor cerebri in a young female with CD during treatment with ketoconazole to manage hypercortisolism.

CASE REPORT

A 12-year old girl was investigated for aggravated obesity. She presented centripetal obesity, moon face and supraclavicular fat pad at her first visit: weight 61 kg, height 151 cm, body mass index 26.7 kg/m², Tanner stage M3P3. Cushing’s syndrome was suspected because of elevated 24-h-urinary free cortisol (UFC) 538 ug/dL (14,848 nmol/L) [normal range: 37-136 ug/dL (normal range: 1,021-3,753 nmol/L)], midnight serum cortisol 14.37 ug/dL (397 nmol/L) and overnight 1 mg dexamethasone suppression of 13.2 µg/dL (364 nmol/L) [normal: < 1.8 µg/dL (50 nmol/L)]. Plasma ACTH was 58 pg/mL (12.76 pmol/L) [normal range: 10-52 pg/dL, (normal range: 2.2-11.4 pmol/L)]. Pituitary magnetic resonance image (MRI) was normal.

A bilateral simultaneous inferior petrosal sinus sampling was performed and showed significant plasma ACTH response to CRH, from 26.6 pg/mL (5.85 pmol/L) to 1,250 pg/ml (275 pmol/L) (Table 1), determining CD diagnosis. Ketoconazole was administered to control the disease before transsphenoidal surgery. Treatment started with a 200 mg/day dose, and was gradually increased for 8 months, based on Cushing’s syndrome parameters. At the 800 mg/day dose, the patient recovered her growth rate, lost 10% of body weight and normalized her 24-h UFC (Table 2).

Four weeks after the last highest dose of ketoconazole, the patient reported a frontal headache with purulent nasal discharge, which led to sinusitis diagnosis and was treated with amoxicillin. Six weeks after this first presentation, the patient complained of frontal headache, myalgia and vomiting, a picture that was interpreted as recurrent sinusitis and treated with azithromycin for 6 days. No symptomatic relief was observed, and she reported a black spot on her right temporal visual field. Ophthalmologic evaluation identified significant bilateral papilloedema (Figure 1A). Brain MRI remained normal and lumbar puncture confirmed elevated CSF opening pressure of 350 mm H₂O, with normal liquor content. All symptoms and papilloedema were solved after treatment with acetazolamide at 750 mg/day dose (Figure 1B). It should be noted that ketoconazole dose was not decreased during the treatment.

DISCUSSION AND CONCLUSION

Scattered cases of benign intracranial hypertension or pseudotumor cerebri have been described after CD control with pituitary surgery, or administration of drugs, including metyrapone, aminoglutethimide and mitotane (1,3-4). This is the first well-characterized report of pseudotumor cerebri in a patient treated with ketoconazole for hypercortisolism.

Ketoconazole is an antifungal agent, an imidazole derivative, which has putative extra-adrenal actions (12,13), and shows inhibitory effects on adrenal and gonadal steroidogenesis linked to the restriction of cytochrome P-450 enzymes, including P450 (scc), P450 (17 α lyase), and P450 (11 β/18). In CD, ketoconazole is used before surgery, as adjuvant therapy, or in subjects who refused or had any contraindications to surgery (12). There is substantial accumulated experience on the use of ketoconazole in hypercortisolism because of its effectiveness as monotherapy, and its favorable side effect profile (14). Common side effects are gastrointestinal upset and skin rashes. Liver enzyme dysfunction may occur in up to 10% of the cases. Recommended starting dose is 200 mg twice a day, increasing to 1,200 mg/day, divided in four doses (15,16).

Castinetti and cols. (12) described thirty-eight patients with CD treated for hypercortisolism with ketoconazole. Rare side effects were observed, inclu-


...ding diarrhea and moderate liver enzyme dysfunction, when using 1,200 mg/day. No adrenal insufficiency or pseudotumor cerebri were observed in this adult sample. Moreover, ketoconazole was used for up to 13 years in a cohort of fifty four patients with CD, with few side-effects: 18% showed adrenal insufficiency, and no case of pseudotumor cerebri was reported, including in 14-year old patients (16). Recently, ketoconazole was associated with cabergoline in part of a cohort of patients with CD unsuccessfully treated with transsphenoidal surgery (17), and no cases of benign intracranial hypertension were detected, although full normalization UFC excretion was targeted in two-thirds of the patients.

Adrenal insufficiency has been described with low doses of ketoconazole – from 200 to 400 mg/day (16). Our patient was using an 800 mg/day dose, which could also cause an adrenal insufficiency crisis. Nonetheless, results of her laboratory exams at 800 mg/day dose showed normalized UFC excretion and serum cortisol levels (Table 2). Her condition improved with the treatment for intracranial hypertension, and the dose of ketoconazole was not reduced.

Abrupt cessation of steroid administration may cause a substantial increase in resistance to cerebrospinal fluid flow (18,19). However, our patient was using ketoconazole for a long period and the dose was increased slowly, as showed in table 2.

In summary, this case emphasizes the association between pseudotumor cerebri and ketoconazole therapy in CD, especially for the treatment of hypercortisolism in children, as this is a group of patients more susceptible to and at major risk for this disorder.

Table 1. Bilateral simultaneous inferior petrosal sinus sampling with CRH

<table>
<thead>
<tr>
<th>ACTH</th>
<th>Right side ACTH</th>
<th>Left side ACTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 min pg/ml (pmol/L)</td>
<td>99.4 (21.8)</td>
<td>26.6 (5.8)</td>
</tr>
<tr>
<td>3 min pg/ml (pmol/L)</td>
<td>144 (31.7)</td>
<td>737 (162.2)</td>
</tr>
<tr>
<td>5 min pg/ml (pmol/L)</td>
<td>236 (52.0)</td>
<td>&gt; 1250 (&gt; 275)</td>
</tr>
<tr>
<td>10 min pg/ml (pmol/L)</td>
<td>269 (59.0)</td>
<td>960 (211.2)</td>
</tr>
<tr>
<td>20 min pg/ml (pmol/L)</td>
<td>270 (59.4)</td>
<td>1160 (255)</td>
</tr>
</tbody>
</table>

Table 2. Laboratory results according to Ketoconazole (Kt) doses

<table>
<thead>
<tr>
<th></th>
<th>Kt 200 mg/d</th>
<th>Kt 400 mg/d</th>
<th>Kt 600 mg/d</th>
<th>Kt 800 mg/d</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 hUFC ug/dL (nmol/L)</td>
<td>538 (14849)</td>
<td>282 (7783)</td>
<td>110 (3036)</td>
<td>54.6 (1506)</td>
</tr>
<tr>
<td>ACTH pg/mL (pmol/l)</td>
<td>58 (12.8)</td>
<td>132 (29)</td>
<td>177 (39)</td>
<td>149 (33)</td>
</tr>
<tr>
<td>Cortisol ug/dl (nmol/l)</td>
<td>9.1 (251)</td>
<td>22.7 (626)</td>
<td>18 (497)</td>
<td>17 (469)</td>
</tr>
<tr>
<td>SDHEA ug/dl (nmol/l)</td>
<td>64 (1.73)</td>
<td>86.2 (2.32)</td>
<td>137 (3.70)</td>
<td>86.2 (2.32)</td>
</tr>
</tbody>
</table>

UFC: urinary free cortisol, Roche Elecsys Immunoassay, normal range: 37-136 ug/dL (normal range: 1021-3753 nmol/L); ACTH: Immulite® Immunoassay-DPC, normal range: 10-52 pg/mL (normal range: 2.2-11.4 pmol/L); cortisol: Electrochemiluminescence. Modular-Roche, normal range: 6.2-19.4 ug/dl (normal range: 171-541 nmol/L); SDHEA: Electrochemiluminescence. Modular-Roche, normal range: 33.9-280 ug/dl (normal range: 0.91-7.6 nmol/L).

Figure 1. (A) Patient with papilloedema. (B) Resolution of papilloedema after treatment.
Acknowledgements: We would like to thank Davidson Alba and Paula B. de Lima for helping us to assist this patient. FC was supported by a scholarship from CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior), a Brazilian funding agency of the Ministry of Education.

Disclosure: no potential conflict of interest relevant to this article was reported.

REFERENCES